论文部分内容阅读
为了观察雾化吸入爱喘乐（溴化异丙托品）对慢性阻塞性肺疾病（ＣＯＰＤ）患者肺功能，尤其是气道阻力的影响，对４０例ＣＯＰＤ患者随机分为雾化吸入溴化异丙托品组和吸入生理盐水组，雾化吸入前，二组临床资料和各项肺功能指标均大致相同（Ｐ＞００５）。结果：雾化吸入溴化异丙托品（０．０２５％２ｍｌ）者６０分钟后各项肺功能指标（ＦＶＣ、ＦＥＶ１、ＦＥＦ２５％～７５％、ＰＥＦＲ）均有不同程度的改善（Ｐ＜００５～００１），尤其是气道阻力（Ｒａｗ、Ｇａｗ、ｓＲａｗ、ｓＧａｗ）明显降低（Ｐ＜００１）。吸入生理盐水组各项肺功能指标均无改变（Ｐ＞００５）。
In order to observe the effect of inhalation of Atrastim Bromide (ipratropium bromide) on pulmonary function, especially airway resistance in patients with chronic obstructive pulmonary disease (COPD), 40 patients with COPD were randomly divided into three groups: Ipratropium group and inhalation of saline group, before inhalation, the clinical data of the two groups and the lung function indicators were about the same (P> 0 05). Results: The pulmonary function indexes (FVC, FEV1, FEF25% -75%, PEFR) after inhalation of ipratropium bromide (0.025% 2ml) were all improved to some extent after 60min 05 ~ 001), especially airway resistance (Raw, Gaw, sRaw, sGaw) was significantly lower (P <001). Inhaled saline group of all lung function indicators were not changed (P> 0 05).